SynthesisOncotarget2017
Diagnostic and prognostic value of circulating tumor DNA in gastric cancer: a meta-analysis.
Synthesis in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 41 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Methylation Analysis of Circulating Tumor DNA in Early Diagnosis and Prognostic Stratification in Patients With Gastric Cancer
Gastric Cancer Detection by Liquid Biopsy in Peripheral Blood: A Prospective Study
Who cites it
41 citing papers in PubMed, 5 syntheses or guidelines pooled it, 83 citations in OpenAlex.
- Circulating tumor DNA and prognosis in gastric cancer patients undergoing surgery: meta-analysis and trial sequential analysis.Frontiers in oncology · 2026Pooled it
- Circulating HPV cDNA in the blood as a reliable biomarker for cervical cancer: A meta-analysis.PloS one · 2020Pooled it
- Association of epicardial adipose tissue with non-alcoholic fatty liver disease: a meta-analysis.Hepatology international · 2019Pooled it
- Association Between Liquid Biopsy and Prognosis of Gastric Cancer Patients: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Diagnostic Value of Concentration of Circulating Cell-Free DNA in Breast Cancer: A Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Trial
- Circulating Tumour DNA and Extracellular Vesicle-Associated DNA as Biomarkers for Cancer Detection: A Systematic Review and Meta-Analysis.Journal of extracellular biology · 2026Article
- Therapeutic Frontiers in Gastroesophageal Cancer: Contemporary Concepts in Management and Therapy.International journal of molecular sciences · 2025Review
- Association between FGF10 expression and gland-forming differentiation pattern in gastric adenocarcinoma: An immunohistochemical analysis.Oncology letters · 2025Article
- Review
- Liquid biopsy for gastric cancer: Techniques, applications, and future directions.World journal of gastroenterology · 2024Review
- Clinical applications and perspectives of circulating tumor DNA in gastric cancer.Cancer cell international · 2024Review
- Concordance analysis of cerebrospinal fluid with the tumor tissue for integrated diagnosis in gliomas based on next-generation sequencing.Pathology oncology research : POR · 2023Article
- Review
- Application progress of liquid biopsy in gastric cancer.Frontiers in oncology · 2022Review
- Role of Circulating Tumor DNA in Gastrointestinal Cancers: Current Knowledge and Perspectives.Cancers · 2021Review
- MSI Analysis in Solid and Liquid Biopsies of Gastroesophageal Adenocarcinoma Patients: A Molecular Approach.International journal of molecular sciences · 2021Article
- Liquid biopsy as an option for predictive testing and prognosis in patients with lung cancer.Molecular medicine (Cambridge, Mass.) · 2021Article
- Methylation status and long-fragment cell-free DNA are prognostic biomarkers for gastric cancer.Cancer medicine · 2021Observational
- Precision Medicine Approaches to Prevent Gastric Cancer.Gut and liver · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCirculating tumor DNA (ctDNA) has offered a minimally invasive approach for detection and measurement of gastric cancer (GC). However, its diagnostic and prognostic value in gastric cancer still remains unclear.
resultsA total of 16 studies comprising 1193 GC patients met our inclusion criteria. The pooled sensitivity and specificity were 0.62 (95% confidence intervals (CI) 0.59-0.65) and 0.95 (95% CI 0.93-0.96), respectively. The AUSROC (area under SROC) curve was 0.94 (95% CI 0.89-0.98). The results showed that the presence of certain ctDNA markers was associated with larger tumor size (OR: 0.26, 95% CI 0.11-0.61, p = 0.002), TNM stage (I + II/III + IV, OR: 0.11, 95% CI 0.07-0.17, p = 0.000), as well as H. pylori infection. (H.p negative/H.p positive, OR: 0.57, 95% CI 0.36-0.91, p = 0.018). Moreover, there was also a significant association between the presence of ctDNA and worse overall survival (HR 1.77, 95% CI 1.38-2.28, p < 0.001), as well as disease-free survival (HR 4.36, 95% CI 3.08-6.16, p < 0.001). MATERIALS AND
methodsPubmed, Embase, Cochrane Library and Web of Science databases were searched for relating literature published up until November 30, 2016. Diagnostic accuracy variables were pooled by the Meta-Disc software. Engauge Digitizer and Stata software were applied for prognostic data extraction and analysis.
conclusionsOur meta-analysis indicates the detection of certain ctDNA targets is significantly associated with poor prognosis of GC patients, with high specificity and relatively moderate sensitivity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.